CJC-1295 + Ipamorelin is a peptide combination being investigated for its effects on growth hormone (GH) signaling. CJC-1295 is a long-acting analogue of growth hormone–releasing hormone (GHRH), while ipamorelin is a growth hormone secretagogue that acts through the ghrelin receptor pathway. Research on CJC-1295 has demonstrated sustained increases in GH and IGF-1 in healthy adults.
This combination is of interest in research examining pituitary signaling, GH secretion, IGF-1 activity, and endocrine physiology. However, clinical evidence specifically evaluating the combined use of CJC-1295 and ipamorelin remains limited, and the FDA has identified safety and quality concerns surrounding compounded CJC-1295 and ipamorelin products.
Research Focus
Growth hormone signaling
GHRH and ghrelin-receptor pathways
GH and IGF-1 activity
Pituitary hormone secretion
Peptide pharmacology and endocrine research
Research Status: Investigational Not FDA-approved for human therapeutic use.
